11 unknown. 11 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Unknown 11 |
| Phase 1 | 2 | Unknown 2 |
Follow dalpiciclib: new trials by email Literature Review of dalpiciclib trials Research Report on dalpiciclib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Dalpiciclib Combined With Letrozole in HR+/HER2 - Gynecologic Solid Tumors Dalpiciclib plus letrozole - Recurrent Ovarian Carcinoma | Phase 2 | Unknown | Fengzhi Feng | 30 | 2023-11-17 | 2024-02-06 |
| Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial. dalpiciclib; fluvestrant; compound gossypol acetate tablets - Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed | Phase 2 | Unknown | Zhejiang Cancer Hospital | 53 | 2023-08-01 | 2023-11-15 |
| Dalpiciclib Plus Fulvestrant With Pyrotinib in Hormone Receptor-positive, HER2-low Advanced Breast Cancer That Progressed on Previous CDK4/6i Plus AI Therapy Dalpiciclib, Pyrotinib, Fulvestrant - Breast Cancer | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2023-05-01 | 2023-04-10 |
| Exploring Whether Disease-free Intervals Can Guide Endocrine Combined Targeted Therapy for ER+/HER2+ Advanced Breast Cancer (T-sunflower) Trastuzumab, pyrotinib, Dalpiciclib - Metastatic Breast Cancer | Phase 2 | Unknown | Fudan University | 126 | 2022-11-01 | 2022-10-13 |
| Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy for HR +/HER2 + Advanced Breast Cancer Trastuzumab, Pyrotinib Combined With Dalpiciclib and Endocrine Therapy - Breast Neoplasm Female | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 52 | 2022-10-20 | 2022-10-19 |
| Dalpiciclib Combined With Letrozole in Neoadjuvant Treatment of Stage Ⅱ-Ⅲ HR-positive/HER2-negative Breast Cancer Dalpiciclib - Solid Tumor | Phase 2 | Unknown | Hebei Medical University Fourth Hospital | 30 | 2022-09-10 | 2022-08-23 |
| Dalpiciclib, Fulvestrant, Trastuzumab and Pertuzumab in HR Positive, HER2 Positive Metastatic Breast Cancer Dalpiciclib, Fulvestrant, Pertuzumab - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 72 | 2022-09-01 | 2024-02-26 |
| Pyrotinib Combined With Trastuzumab,Dalpiciclib and Letrozole for HR+/HER2+ Breast Cancer pyrotinib combined with trastuzumab, dalpiciclib and letrozole - Breast Cancer | Phase 2 | Unknown | Yantai Yuhuangding Hospital | 30 | 2022-08-04 | 2023-04-06 |
| Neoadjuvant Dalpiciclib Plus Letrozole for HR+/HER2- Breast Cancer dalpiciclib plus letrozole - Breast Cancer | Phase 2 | Unknown | The Affiliated Hospital of Qingdao University | 35 | 2022-08-01 | 2022-08-23 |
| mFOLFOX6 Combined With Dalpiciclib in Patients With Metastatic Colorectal Cancer Dalpiciclib, Oxaliplatin injection, Calcium folinate - Advanced/Metastatic Colorectal Cancer | Phase 2 | Unknown | Sixth Affiliated Hospital, Sun Yat-sen University | 18 | 2022-07-20 | 2023-02-28 |
| Pyrotinib, Dalpiciclib(SHR6390) and Endocrine Therapy in Subjects With Dual-receptor Positive(ER+/HER2+) Advanced Breast Cancer Dalpiciclib, Pyrotinib, Letrozole - Breast Cancer | Phase 1 / Phase 2 | Unknown | Fudan University | 59 | 2019-05-12 | 2023-03-07 |
Breast Neoplasms (6) · Colorectal Neoplasms (1) · Ovarian Neoplasms (1)
Fudan University (3) · Fengzhi Feng (1) · Hebei Medical University Fourth Hospital (1) · Peking University Cancer Hospital & Institute (1) · Sixth Affiliated Hospital, Sun Yat-sen University (1) · The Affiliated Hospital of Qingdao University (1) · Tianjin Medical University Cancer Institute and Hospital (1) · Yantai Yuhuangding Hospital (1) · Zhejiang Cancer Hospital (1)
China (8)
Guangdong Qiao (1) · Xiaojian Wu, Ph.D (1)